Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
392 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Refractory Multiple Myeloma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Refractory Multiple Myeloma - Pipeline Review, H2 2014', provides an overview of the Refractory Multiple Myeloma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 8 Global Markets Direct Report Coverage 8 Refractory Multiple Myeloma Overview 9 Therapeutics Development 10 Pipeline Products for Refractory Multiple Myeloma - Overview 10 Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis 11 Refractory Multiple Myeloma - Therapeutics under Development by Companies 12 Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 16 Refractory Multiple Myeloma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Refractory Multiple Myeloma - Products under Development by Companies 19 Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes 21 Refractory Multiple Myeloma - Companies Involved in Therapeutics Development 22 Bristol-Myers Squibb Company 22 Johnson & Johnson 23 Kyowa Hakko Kirin Co., Ltd. 24 Sanofi 25 Eli Lilly and Company 26 GlaxoSmithKline plc 27 Genentech, Inc. 28 Piramal Enterprises Limited 29 Prolexys Pharmaceuticals, Inc. 30 ZIOPHARM Oncology, Inc. 31 Millennium Pharmaceuticals, Inc. 32 Novartis AG 33 Astellas Pharma Inc. 34 Pfizer Inc. 35 Sigma-Tau S.p.A. 36 Astex Pharmaceuticals, Inc. 37 Exelixis, Inc. 38 Celgene Corporation 39 Onyx Pharmaceuticals, Inc. 40 Incyte Corporation 41 Immunomedics, Inc. 42 Oncolytics Biotech Inc. 43 Patrys Limited 44 Curis, Inc. 45 Pharmacyclics, Inc. 46 Array BioPharma Inc. 47 MorphoSys AG 48 Senesco Technologies, Inc. 49 Threshold Pharmaceuticals, Inc. 50 Synta Pharmaceuticals Corp. 51 Dicerna Pharmaceuticals, Inc. 52 Acceleron Pharma, Inc. 53 Altor BioScience Corporation 54 Arno Therapeutics, Inc. 55 Stemline Therapeutics, Inc. 56 Onconova Therapeutics, Inc. 57 Acetylon Pharmaceuticals, Inc. 58 Pharma Mar, S.A. 59 CureTech Ltd. 60 AbbVie Inc. 61 Oncopeptides AB 62 Senhwa Biosciences, Inc. 63 Refractory Multiple Myeloma - Therapeutics Assessment 64 Assessment by Monotherapy Products 64 Assessment by Combination Products 65 Assessment by Target 66 Assessment by Mechanism of Action 70 Assessment by Route of Administration 75 Assessment by Molecule Type 77 Drug Profiles 79 ixazomib citrate - Drug Profile 79 daratumumab - Drug Profile 82 ibrutinib - Drug Profile 84 carfilzomib - Drug Profile 89 elotuzumab - Drug Profile 92 plitidepsin - Drug Profile 94 bendamustine hydrochloride - Drug Profile 96 AT-9283 - Drug Profile 98 AT-7519 - Drug Profile 100 PAT-SM6 - Drug Profile 103 ruxolitinib phosphate - Drug Profile 105 filanesib - Drug Profile 109 darinaparsin - Drug Profile 111 ALT-801 - Drug Profile 113 pidilizumab - Drug Profile 115 PM-00104 - Drug Profile 117 pomalidomide - Drug Profile 118 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 122 DKN-01 - Drug Profile 124 Melflufen - Drug Profile 126 Circularly Permuted TRAIL - Drug Profile 128 alisertib - Drug Profile 129 linsitinib - Drug Profile 133 milatuzumab - Drug Profile 136 AR-42 - Drug Profile 138 PRLX-93936 - Drug Profile 140 oprozomib - Drug Profile 142 cabozantinib s-malate - Drug Profile 144 SNS-01T - Drug Profile 147 ganetespib - Drug Profile 148 SL-401 - Drug Profile 152 TH-302 - Drug Profile 154 P-276 - Drug Profile 161 MOR-202 - Drug Profile 163 KW-2478 - Drug Profile 165 palbociclib - Drug Profile 166 marizomib - Drug Profile 169 luminespib - Drug Profile 171 plerixafor - Drug Profile 174 ricolinostat - Drug Profile 176 LGH-447 - Drug Profile 178 selinexor - Drug Profile 179 tabalumab - Drug Profile 181 daratumumab - Drug Profile 183 BMS-833923 - Drug Profile 185 dalantercept - Drug Profile 187 SAR-650984 - Drug Profile 189 dasatinib - Drug Profile 190 pelareorep - Drug Profile 193 rigosertib sodium - Drug Profile 197 MLN-0128 - Drug Profile 201 ulocuplumab - Drug Profile 203 tipifarnib - Drug Profile 204 SST-0001 - Drug Profile 206 veliparib - Drug Profile 207 silmitasertib - Drug Profile 209 afuresertib hydrochloride - Drug Profile 211 CUDC-907 - Drug Profile 213 MV-NIS Vaccine - Drug Profile 215 venetoclax - Drug Profile 217 RG-7598 - Drug Profile 220 LGH-447 - Drug Profile 222 DCRM-1711 - Drug Profile 223 GSK-2857916 - Drug Profile 224 Refractory Multiple Myeloma - Recent Pipeline Updates 225 Refractory Multiple Myeloma - Dormant Projects 376 Refractory Multiple Myeloma - Discontinued Products 377 Refractory Multiple Myeloma - Product Development Milestones 378 Featured News & Press Releases 378 Appendix 387 Methodology 387 Coverage 387 Secondary Research 387 Primary Research 387 Expert Panel Validation 387 Contact Us 388 Disclaimer 388
List of Tables Number of Products under Development for Refractory Multiple Myeloma, H2 2014 14 Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Late Stage Development, H2 2014 21 Comparative Analysis by Clinical Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Investigation by Universities/Institutes, H2 2014 25 Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2014 26 Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2014 27 Refractory Multiple Myeloma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 28 Refractory Multiple Myeloma - Pipeline by Sanofi, H2 2014 29 Refractory Multiple Myeloma - Pipeline by Eli Lilly and Company, H2 2014 30 Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H2 2014 31 Refractory Multiple Myeloma - Pipeline by Genentech, Inc., H2 2014 32 Refractory Multiple Myeloma - Pipeline by Piramal Enterprises Limited., H2 2014 33 Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc.., H2 2014 34 Refractory Multiple Myeloma - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 35 Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 36 Refractory Multiple Myeloma - Pipeline by Novartis AG, H2 2014 37 Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2014 38 Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H2 2014 39 Refractory Multiple Myeloma - Pipeline by Sigma-Tau S.p.A., H2 2014 40 Refractory Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 41 Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2014 42 Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H2 2014 43 Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 44 Refractory Multiple Myeloma - Pipeline by Incyte Corporation, H2 2014 45 Refractory Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2014 46 Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2014 47 Refractory Multiple Myeloma - Pipeline by Patrys Limited, H2 2014 48 Refractory Multiple Myeloma - Pipeline by Curis, Inc., H2 2014 49 Refractory Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H2 2014 50 Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2014 51 Refractory Multiple Myeloma - Pipeline by MorphoSys AG., H2 2014 52 Refractory Multiple Myeloma - Pipeline by Senesco Technologies, Inc.., H2 2014 53 Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 54 Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2014 55 Refractory Multiple Myeloma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2014 56 Refractory Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H2 2014 57 Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2014 58 Refractory Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2014 59 Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2014 60 Refractory Multiple Myeloma - Pipeline by Onconova Therapeutics, Inc., H2 2014 61 Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 62 Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2014 63 Refractory Multiple Myeloma - Pipeline by CureTech Ltd., H2 2014 64 Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H2 2014 65 Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2014 66 Refractory Multiple Myeloma - Pipeline by Senhwa Biosciences, Inc., H2 2014 67 Assessment by Monotherapy Products, H2 2014 68 Assessment by Combination Products, H2 2014 69 Number of Products by Stage and Target, H2 2014 72 Number of Products by Stage and Mechanism of Action, H2 2014 76 Number of Products by Stage and Route of Administration, H2 2014 80 Number of Products by Stage and Molecule Type, H2 2014 82 Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2014 229 Refractory Multiple Myeloma - Dormant Projects, H2 2014 379 Refractory Multiple Myeloma - Discontinued Products, H2 2014 380
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
